CAS: 763120-58-7; 1H-Pyrazole-4-Boronic Acid

该化合物是一种多用途的boronic酸衍生物,广泛用于铃木-米亚乌拉交叉反应,这是形成有机合成碳-碳联系的关键方法,其阳极度可增强反应性和选择性,使其在制药和农用化学应用中具有价值.该化合物在标准条件下具有良好稳定性,并与一系列功能组相容,有助于不同的合成途径.其高纯度和一贯性能确保催化转化的可靠结果.此外,1H-Pyrazol-4-yl)boronic酸是生物活性化合物(包括动脉抑制剂和其他外循环型人造假肢)发育的关键中间体.

结构式图片

相似化合物

269410-08-4 1111732-81-0 1188405-87-9

欧盟法规

C&L通报

上下游产品

Triisopropyl borate 5-(2-chloro-4-(1H-pyrazol-4-yl)phenyl)-1,3,4-thiadiazol-2-amine

合成工艺路线路线简述

    硼酸三异丙酯,4-Iodo-1-(Triisopropylsilyl)-1H-Pyrazole置于正丁基锂体系中,化学反应 0.5H,以72%的收率获得产物4-吡唑硼酸
    参考文献:一种氮未取代吡唑和吲唑类硼酸的制备方法
    标题:一种氮未取代吡唑和吲唑类硼酸的制备方法
    摘要:一种氮未取代吡唑和吲唑类硼酸的制备方法,以氮未取代卤代吡唑及其衍生物或氮未取代卤代吲唑及其衍生物和三异丙基氯硅烷溶于有机溶剂中进行反应,反应生成三异丙基硅基保护的卤代吡唑或者卤代吲唑化合物,再与正丁基锂发生锂溴交换反应,加入硼酸酯引入硼原子,水解后高收率的到得了氮未取代吡唑或吲唑类硼酸.

    专利信息


    专利号:US-10995078-B2
    优先权日:2013-03-13
    标 题:Compounds and compositions for inhibition of FASN
    发明人:BAIR KENNETH W; LANCIA JR DAVID R; LI HONGBIN; LOCH JAMES; LU WEI; MARTIN MATTHEW W; MILLAN DAVID S; SCHILLER SHAWN E R; TEBBE MARK J
    权利人:FORMA THERAPEUTICS INC
    摘要:The present invention relates to compounds and composition for inhibition of FASN, their synthesis, applications, and antidotes. An illustrative compound of the invention is shown below:

    专利号:WO-2011050245-A1
    优先权日:2009-10-23
    标 题:Bicyclic heteroaryls as kinase inhibitors
    发明人:FENG YANGBO; CHEN YEN TING; SESSIONS HAMPTON; MISHRA JITENDRA K; CHOWDHURY SARWAT; YIN YAN; LOGRASSO PHILIP; LUO JUN-LI; BANNISTER THOMAS; SCHROETER THOMAS
    权利人:FENG YANGBO; CHEN YEN TING; SESSIONS HAMPTON; MISHRA JITENDRA K; CHOWDHURY SARWAT; YIN YAN; LOGRASSO PHILIP; LUO JUN-LI; BANNISTER THOMAS; SCHROETER THOMAS
    摘要:The invention is directed to heteroaryl compounds useful as inhibitors of various kinase enzymes. In various embodiments, the invention provides a heteroaryl compound having inhibitory bioactivity with respect to a Rho kinase, an AKT kinase, a p70S6K kinase, a LIM kinase, an IKK kinase, a Flt kinase, an Aurora kinase, or a Src kinase, or any combination thereof. Compounds of the invention include bicyclic heteroaryl compounds of formula (I), which can contain a bridging nitrogen atom at a ring junction. The invention further provides methods of synthesis of compounds of the invention, pharmaceutical compositions, pharmaceutical combinations, and methods of treatment of malconditions using compounds of the invention.

    专利号:US-9988371-B2
    优先权日:2014-06-03
    标 题:Benzimidazole analogues and related methods
    发明人:LI HONG-YU; FRETT BRENDAN; SANTORO MASSIMO; CARLOMAGNO FRANCESCA
    权利人:UNIV ARIZONA; UNIV FEDERICO II; UNIV ARIZONA
    摘要:The invention relates to compounds of the formula (VIII) wherein the moieties R 1 , R 2 , R 3 , R 4 , and R 5 are as defined in the specification, and salts thereof, as well as their use, methods of use for them, methods of their synthesis, and the like. The compounds are protein tyrosine kinase inhibitors and can be used in the treatment of various cancer diseases and cancer-associated pain.

    专利号:EP-1784396-B8
    优先权日:2004-08-26
    标 题 :Pyrazole-substituted aminoheteroaryl compounds as protein kinase inhibitors
    发明人:CUI JINGRONG JEAN; FUNK LEE ANDREW; JIA LEI; KUNG PEI-PEI; MENG JERRY JIALUN; NAMBU MITCHELL DAVID; PAIRISH MASON ALAN; SHEN HONG; TRAN-DUBE MICHELLE BICH
    权利人:PFIZER
    摘要:Compounds of formula (1) are provided, as well as methods for their synthesis and use. Preferred compounds are potent inhibitors of the c-Met protein kinase, and are useful in the treatment of abnormal cell growth disorders, such as cancers.

    专利号:WO-2010001220-A1
    优先权日:2008-07-01
    标 题 :New 1,2,4-triazine derivatives and biological applications thereof
    发明人:DESROY NICOLAS; DENIS ALEXIS; GERUSZ VINCENT; OLIVEIRA CHRYSTELLE; VONGSOUTHI VANIDA; MOREAU FRANCOISE; ESCAICH SONIA
    权利人:MUTABILIS SA; DESROY NICOLAS; DENIS ALEXIS; GERUSZ VINCENT; OLIVEIRA CHRYSTELLE; VONGSOUTHI VANIDA; MOREAU FRANCOISE; ESCAICH SONIA
    摘要:The invention relates to new 1,2,4-triazine derivatives of formula (I): wherein A, B, R2 and Y are defined in the application, their preparation and intermediates, their use as drugs and pharmaceutical compositions and associations containing them. The compounds of formula (I) are capable of inhibiting bacterial heptose synthesis.

    专利号:WO-2014024119-A1
    优先权日:2012-08-06
    标 题:Heterocyclic amides as itk inhibitors
    发明人:KUMAR SUKEERTHI; THOMAS ABRAHAM; CHIKHALE RAJENDRA PRAKASH; WAGHMARE NAYAN TATERAO; KADLAG NANASAHEB; KHAIRATKAR-JOSHI NEELIMA; SHAH DAISY MANISH
    权利人:GLENMARK PHARMACEUTICALS SA
    摘要:The present invention is directed to heterocyclic amide compounds of formula (I) as Tec kinase inhibitors, in particular ITK (interleukin-2 inducible tyrosine kinase) inhibitors. Also provided herein are processes for preparing compounds described herein, intermediates used in their synthesis, pharmaceutical compositions thereof, and methods for treating or preventing diseases, conditions and/or disorders mediated by ITK.
    硼心化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.boroncore.com
    电话: 86 0571 88487672👤
    📞硼心化工有限公司 ⚠️参考联系方式

    销售电话:86 0571 88487672
    邮箱:sales@boroncore.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    重庆艾思摩尔科技有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.acemol.com
    电话: 023-86822659,👤
    📞重庆艾思摩尔科技有限公司 ⚠️参考联系方式

    销售电话:023-86822659,
    邮箱:sales@acemol.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知